Prothena (PRTA) Competitors $8.77 +0.21 (+2.45%) Closing price 04:00 PM EasternExtended Trading$8.72 -0.04 (-0.51%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTA vs. APGE, IMCR, DYN, CDTX, TWST, TVTX, BHVN, AUPH, SDGR, and EVOShould you be buying Prothena stock or one of its competitors? The main competitors of Prothena include Apogee Therapeutics (APGE), Immunocore (IMCR), Dyne Therapeutics (DYN), Cidara Therapeutics (CDTX), Twist Bioscience (TWST), Travere Therapeutics (TVTX), Biohaven (BHVN), Aurinia Pharmaceuticals (AUPH), Schrodinger (SDGR), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Prothena vs. Its Competitors Apogee Therapeutics Immunocore Dyne Therapeutics Cidara Therapeutics Twist Bioscience Travere Therapeutics Biohaven Aurinia Pharmaceuticals Schrodinger Evotec Apogee Therapeutics (NASDAQ:APGE) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Do insiders and institutionals believe in APGE or PRTA? 79.0% of Apogee Therapeutics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 42.8% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 9.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, APGE or PRTA? Apogee Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Prothena has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Which has better valuation & earnings, APGE or PRTA? Prothena has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$182.15M-$4.13-9.27Prothena$135.16M3.49-$122.31M-$5.64-1.55 Do analysts rate APGE or PRTA? Apogee Therapeutics presently has a consensus price target of $99.00, indicating a potential upside of 158.69%. Prothena has a consensus price target of $30.25, indicating a potential upside of 244.93%. Given Prothena's higher probable upside, analysts clearly believe Prothena is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is APGE or PRTA more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Prothena's net margin of -2,929.30%. Apogee Therapeutics' return on equity of -34.65% beat Prothena's return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -34.65% -32.76% Prothena -2,929.30%-62.17%-54.43% Does the media refer more to APGE or PRTA? In the previous week, Apogee Therapeutics had 1 more articles in the media than Prothena. MarketBeat recorded 2 mentions for Apogee Therapeutics and 1 mentions for Prothena. Prothena's average media sentiment score of 0.53 beat Apogee Therapeutics' score of 0.08 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryApogee Therapeutics beats Prothena on 9 of the 15 factors compared between the two stocks. Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTA vs. The Competition Export to ExcelMetricProthenaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$472.09M$3.09B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-1.5521.1631.1525.99Price / Sales3.49396.94474.77122.97Price / CashN/A43.0937.1558.38Price / Book1.458.069.116.38Net Income-$122.31M-$54.72M$3.26B$265.56M7 Day Performance6.30%2.52%2.12%1.89%1 Month Performance34.30%7.54%5.13%1.23%1 Year Performance-58.73%13.01%31.25%21.10% Prothena Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTAProthena3.3009 of 5 stars$8.77+2.5%$30.25+244.9%-61.0%$472.09M$135.16M-1.55130APGEApogee Therapeutics3.5165 of 5 stars$34.65-2.1%$99.00+185.7%-24.8%$1.63BN/A-9.6391IMCRImmunocore1.851 of 5 stars$31.89-0.3%$58.00+81.9%-10.6%$1.61B$310.20M-79.73320Positive NewsDYNDyne Therapeutics3.2983 of 5 stars$11.24+0.7%$34.94+210.8%-74.0%$1.59BN/A-2.91100CDTXCidara Therapeutics3.607 of 5 stars$62.00flat$64.14+3.5%+419.2%$1.57B$1.27M-5.5790TWSTTwist Bioscience4.1868 of 5 stars$27.63+7.8%$49.40+78.8%-40.0%$1.55B$312.97M-19.06990Positive NewsTVTXTravere Therapeutics2.4499 of 5 stars$17.28+2.0%$32.21+86.4%+104.7%$1.51B$233.18M-8.47460BHVNBiohaven3.8442 of 5 stars$13.42-8.9%$58.46+335.5%-64.6%$1.51BN/A-1.43239Trending NewsAnalyst ForecastOptions VolumeGap UpAUPHAurinia Pharmaceuticals2.7024 of 5 stars$11.43+0.5%$12.00+5.0%+83.3%$1.50B$235.13M26.58300Positive NewsSDGRSchrodinger3.0987 of 5 stars$18.63-3.0%$32.75+75.8%-2.5%$1.41B$207.54M-7.51790EVOEvotec1.6259 of 5 stars$3.81-3.1%$5.90+54.9%+14.2%$1.40B$862.40M0.004,827 Related Companies and Tools Related Companies Apogee Therapeutics Competitors Immunocore Competitors Dyne Therapeutics Competitors Cidara Therapeutics Competitors Twist Bioscience Competitors Travere Therapeutics Competitors Biohaven Competitors Aurinia Pharmaceuticals Competitors Schrodinger Competitors Evotec Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTA) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Corporation plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access